Ulrike I. Attenberger1, Matthias Voth2, Andre Luckscheiter3, Stefan Haneder1, Stefan O. Schoenberg4, Henrik J. Michaely1
1Department of Clinical Radiology and Nuclear Medicine, University Medical Center Manheim, Mannheim, Germany; 2Bayer Schering AG, Berlin, Germany; 3University of Heidelberg, Heidelberg, Germany; 4Department of Clinical Radiology and Nuclear Medicine, University Medical Center Manheim , Mannheim, Germany
Since nephrogenic systemic fibrosis (NSF) has been linked to gadolinium-chelate administration in patients with impaired renal function, contrast agent dose and chelate stability have attracted broad attention. Numerous studies have demonstrated linear compounds to be the least stable, whereas the macrocyclic compounds are the most stable. With the approval of gadobutrol, a double concentrated macrocyclic gadolinium chelate became available, characterized by the highest R1-relaxivity among the macrocyclic gadolinium chelates. The aim of this study was to evaluate the enhancement characteristics of gadobutrol and gadoterate meglumine, both injected at a dose level of 0.07 mmol/kg BW, for peripheral MR-angiography.